or Bacilli of Döderlein. Among the most involved microorganisms, the Gardnerella vaginalis plays a leading role, but they can also be involved Mycoplasma hominis, Mobiluncus spp. And Prevotella spp.
greyish-white and foul-smelling, itching and burning in the interior and pain in sexual intercourse.For further information: Bacterial Vaginosis Symptoms
The information on Bacterial Vaginosis - Medicines for the Treatment of Bacterial Vaginosis is not intended to replace the direct relationship between health professional and patient. Always consult your doctor and / or specialist before taking Bacterial Vaginosis - Medicines for the Treatment of Bacterial Vaginosis.
most common among women. This condition is characterized by profound alteration of the normal ecosystem of the vagina. In particular, in bacterial vaginosis there is an imbalance of the microorganisms that make up the so-called saprophytic flora or vaginal microbiota which, under physiological conditions, populate and defend the vaginal environment itself. The result is a "polymicrobial infection capable of establishing, synergistically, conditions suitable for the proliferation of other harmful pathogens. There is thus an alteration in the vaginal flora, with a decrease in Lactobacilli or Bacilli of Döderlein, normally protective microorganisms and responsible for maintaining the slightly acidic vaginal environment (pH 3.8-4.5).
Bacterial vaginosis can be asymptomatic in up to 50% of cases. When present, the symptoms indicative of the infection are: itching, intimate burning and increased vaginal discharge (homogeneous grayish-white secretions, characterized by a bad smell comparable to that of fish).
If not treated properly, bacterial vaginosis can lead to gynecological complications, as well as favoring the transmission of STDs through sexual intercourse.
The following are the classes of drugs most used in the treatment of bacterial vaginosis and some examples of therapy; it is up to the physician to choose the active ingredient and the most suitable dosage for the patient, based on the severity of the disease, the general state of health and its responsiveness to the therapeutic protocol.
The treatment regimens recommended by the Centers of Disease and Control and Prevention (CDC) are for bacterial vaginosis include:
- METRONIDAZOLE: the antibiotic therapy of choice against bacterial vaginosis involves the use of metronidazole as an active ingredient. Orally, it is recommended to take a 500 mg tablet, twice a day, for 7 days. Alternatively, it is possible take a single dose of oral metronidazole (2 g of active ingredient in a single dose). At the moment, the latter is the most cost-effective drug treatment. Furthermore, it is possible to apply the medicine directly into the vagina in the form of a cream (metronidazole 0.75%): generally, the duration of topical therapy is 5 days (once a day) unless further indicated by the treating physician. the first 24 hours after treatment with metronidazole for bacterial vaginosis do not use alcoholic beverages, since the association with this drug can give rise to side effects affecting the gastrointestinal and urogenital systems (disulfiram-like syndrome).
- CLINDAMYCINE: applied locally, this drug is particularly useful for fighting bacterial vaginosis. Generally, the duration of topical therapy, ie with clindamycin cream 2%, one application (equal to 5 grams) in the vagina is 7 days. Alternatively, you can take a 300 mg tablet of the active ingredient orally, twice a day for one week or use the 100 mg vaginal pessaries for three days. In pregnancy, the use of clindamycin cream has been associated with adverse events in the second half of gestation, therefore its use should be limited to the first period. Topical formulations based on clindamycin used for the treatment of bacterial vaginosis reduce efficacy. of latex condoms and diaphragms. Therefore, women who use them cannot rely on these contraceptive methods during therapy.
The prevention of relapses is implemented with: restoration of vaginal pH and normal lactobacillary flora and eradication of anaerobic bacteria.
In general, a follow-up one month after treatment can be considered to verify the efficacy of the chosen therapeutic protocol together with the general practitioner or gynecologist of reference. The simultaneous treatment of the sexual partner must be evaluated according to the case, as it is not always necessary.
